Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of serlopitant (VPD-737) in chronic pruritus
2014-001581-10Phase 2Completed
- Sponsor
- Tigercat Pharma, Inc.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of serlopitant in chronic pruritus (CP) (4 arms), sponsored by Tigercat Pharma, Inc. Primary endpoint: Percent change in VAS from baseline. Started May 2014; status: completed.
02
Drugs
serlopitant
03
Conditions
chronic pruritus (CP)
Beyond the preview
Go deeper on 2014-001581-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001581-10.